NASDAQ:MESO - Mesoblast Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $13.50
  • Forecasted Upside: 191.58 %
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.06 (-1.28%)

This chart shows the closing price for MESO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mesoblast Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MESO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MESO

Analyst Price Target is $13.50
▲ +191.58% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Mesoblast in the last 3 months. The average price target is $13.50, with a high forecast of $18.00 and a low forecast of $6.50. The average price target represents a 191.58% upside from the last price of $4.63.

This chart shows the closing price for MESO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Mesoblast. This rating has held steady since November 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/3/2021Cantor FitzgeraldReiterated RatingOverweightN/A
8/31/2021HC WainwrightReiterated RatingBuy$16.00High
8/31/2021Jefferies Financial GroupDowngradeBuy ➝ HoldHigh
8/31/2021Chardan CapitalLower Price TargetSell$7.50 ➝ $6.50High
4/13/2021Maxim GroupUpgradeHold ➝ BuyN/A
4/7/2021Maxim GroupUpgradeHold ➝ Buy$18.00High
1/19/2021Jefferies Financial GroupDowngradeBuy ➝ HoldLow
12/22/2020Maxim GroupDowngradeBuy ➝ HoldLow
12/15/2020HC WainwrightReiterated RatingBuy$20.00High
12/4/2020Chardan CapitalDowngradeNeutral ➝ Sell$5.50 ➝ $7.50High
11/20/2020HC WainwrightBoost Price TargetBuy$19.00 ➝ $20.00High
10/22/2020Royal Bank of CanadaInitiated CoverageSector Perform$12.00Low
10/5/2020Maxim GroupLower Price Target$22.00 ➝ $18.00Low
10/2/2020HC WainwrightLower Price TargetBuy$21.00 ➝ $19.00High
8/14/2020Maxim GroupBoost Price TargetBuy$16.00 ➝ $22.00High
5/29/2020Maxim GroupInitiated CoverageBuy$16.00High
5/28/2020LADENBURG THALM/SH SHBoost Price TargetBuy$13.00 ➝ $15.25Low
5/28/2020HC WainwrightReiterated RatingPositive ➝ Buy$14.00 ➝ $21.00Low
4/27/2020HC WainwrightReiterated RatingBuy$14.00High
4/9/2020HC WainwrightReiterated RatingBuyN/A
2/28/2020Maxim GroupReiterated RatingBuy$16.00Medium
2/6/2020HC WainwrightReiterated RatingBuy$14.00Low
12/19/2019Dawson JamesInitiated CoverageBuy$14.00Low
11/27/2019Maxim GroupReiterated RatingBuy$16.00Low
11/26/2019HC WainwrightReiterated RatingBuy$8.00High
10/22/2019Cantor FitzgeraldReiterated RatingOverweight$23.00Low
9/12/2019Maxim GroupReiterated RatingBuy$16.00N/A
9/10/2019Cantor FitzgeraldSet Price TargetBuy$23.00Medium
9/10/2019OppenheimerSet Price TargetBuy$10.00N/A
8/30/2019HC WainwrightSet Price TargetBuy$7.00Low
8/30/2019Chardan CapitalSet Price TargetHold$6.00Low
6/12/2019Maxim GroupReiterated RatingBuy$16.00Low
6/5/2019HC WainwrightInitiated CoverageBuy$7.00Low
5/31/2019Chardan CapitalSet Price TargetHold$6.00Medium
5/30/2019Maxim GroupInitiated CoverageBuy$16.00Medium
4/16/2019Maxim GroupReiterated RatingBuyHigh
2/22/2019HC WainwrightReiterated RatingBuyHigh
2/21/2019Maxim GroupReiterated RatingBuy$16.00Medium
1/31/2019HC WainwrightReiterated RatingBuy ➝ Buy$6.50High
12/13/2018OppenheimerSet Price TargetBuy$15.00High
11/26/2018Maxim GroupSet Price TargetBuy$16.00Medium
11/13/2018HC WainwrightSet Price TargetBuy$17.00High
11/12/2018Maxim GroupReiterated RatingBuy$16.00Medium
11/12/2018OppenheimerSet Price TargetBuy$15.00Medium
11/11/2018Cantor FitzgeraldSet Price TargetBuy$23.00High
10/25/2018HC WainwrightSet Price TargetBuy$17.00Medium
10/12/2018Maxim GroupReiterated RatingBuy$16.00Medium
10/2/2018HC WainwrightSet Price TargetBuy$17.00High
10/1/2018Cantor FitzgeraldSet Price TargetBuy$23.00Low
9/20/2018Cantor FitzgeraldSet Price TargetBuy$23.00Low
9/18/2018HC WainwrightSet Price TargetBuy$17.00Low
8/30/2018HC WainwrightSet Price TargetBuy$17.00Low
8/30/2018Cantor FitzgeraldSet Price TargetBuy$23.00Low
7/18/2018Maxim GroupBoost Price TargetBuy ➝ Buy$14.00 ➝ $16.00High
7/17/2018Cantor FitzgeraldSet Price TargetBuy$23.00High
7/17/2018HC WainwrightSet Price TargetBuy$17.00High
7/2/2018HC WainwrightSet Price TargetBuy$17.00High
6/21/2018Cantor FitzgeraldReiterated RatingBuy$23.00High
6/7/2018HC WainwrightInitiated CoverageBuy$17.00High
5/31/2018Cantor FitzgeraldSet Price TargetBuy$23.00High
3/29/2018Maxim GroupSet Price TargetBuy$14.00Low
3/22/2018Credit Suisse GroupDowngradeNeutral ➝ Underperform$6.00Medium
3/7/2018Maxim GroupSet Price TargetBuy$14.00Low
2/28/2018Maxim GroupSet Price TargetBuy$14.00High
2/27/2018Cantor FitzgeraldSet Price TargetBuy ➝ Buy$20.00 ➝ $23.00High
2/22/2018Maxim GroupSet Price TargetBuy$14.00High
2/21/2018Cantor FitzgeraldSet Price TargetBuy$20.00 ➝ $23.00High
1/31/2018Maxim GroupReiterated RatingBuy$14.00Low
1/16/2018Cantor FitzgeraldSet Price TargetBuy$20.00Low
12/20/2017OppenheimerSet Price TargetBuy$16.00Low
12/18/2017Maxim GroupSet Price TargetBuy$14.00High
11/15/2017Maxim GroupSet Price TargetBuy$14.00N/A
11/14/2017OppenheimerSet Price TargetBuy$16.00N/A
9/26/2017Maxim GroupReiterated RatingBuy$14.00Low
8/31/2017CIBCInitiated CoverageOutperform ➝ Outperform$16.00High
8/31/2017OppenheimerInitiated CoverageOutperform$16.00High
8/30/2017Maxim GroupSet Price TargetBuy$14.00High
8/30/2017Cantor FitzgeraldReiterated RatingBuy$20.00High
8/23/2017Cantor FitzgeraldReiterated RatingBuyMedium
8/16/2017Cantor FitzgeraldSet Price TargetBuy$20.00Medium
8/16/2017Maxim GroupSet Price TargetBuy$14.00High
7/18/2017Credit Suisse GroupSet Price TargetHold$11.00Low
6/8/2017Cantor FitzgeraldReiterated RatingOverweightMedium
6/7/2017Cantor FitzgeraldInitiated CoverageBuy ➝ Buy$20.00High
5/25/2017Maxim GroupSet Price TargetBuy$14.00Low
4/11/2017Maxim GroupReiterated RatingBuy$14.00Low
4/3/2017ScotiabankReiterated RatingHold$8.50Low
3/31/2017Maxim GroupReiterated RatingBuy$14.00High
3/15/2017Maxim GroupReiterated RatingBuy ➝ Positive$14.00Medium
3/7/2017Maxim GroupReiterated RatingBuy$14.00N/A
2/27/2017Maxim GroupSet Price TargetBuy$14.00N/A
(Data available from 1/17/2017 forward)

News Sentiment Rating

-0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 5 very negative mentions
  • 1 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
  • 0 very positive mentions
  • 6 positive mentions
  • 4 negative mentions
  • 4 very negative mentions
  • 1 very positive mentions
  • 4 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 9 positive mentions
  • 14 negative mentions
  • 4 very negative mentions
  • 0 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mesoblast logo
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.
Read More

Today's Range

Now: $4.63
Low: $4.41
High: $4.69

50 Day Range

MA: $5.48
Low: $4.17
High: $7.09

52 Week Range

Now: $4.63
Low: $3.91
High: $11.69


84,483 shs

Average Volume

84,990 shs

Market Capitalization

$600.69 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Mesoblast?

The following Wall Street analysts have issued research reports on Mesoblast in the last twelve months: Cantor Fitzgerald, Chardan Capital, HC Wainwright, Jefferies Financial Group Inc., Maxim Group, and Zacks Investment Research.
View the latest analyst ratings for MESO.

What is the current price target for Mesoblast?

3 Wall Street analysts have set twelve-month price targets for Mesoblast in the last year. Their average twelve-month price target is $13.50, suggesting a possible upside of 191.6%. Maxim Group has the highest price target set, predicting MESO will reach $18.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $6.50 for Mesoblast in the next year.
View the latest price targets for MESO.

What is the current consensus analyst rating for Mesoblast?

Mesoblast currently has 1 sell rating, 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MESO, but not buy more shares or sell existing shares.
View the latest ratings for MESO.

How do I contact Mesoblast's investor relations team?

Mesoblast's physical mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company's listed phone number is (139) 639-6036 and its investor relations email address is [email protected] The official website for Mesoblast is